• Firm commitments to raise ~$7.1 million via a placement
• 2-for-5 pro rata non-renounceable entitlement offer to raise up to ~$17.1 million
• $20 million strategic convertible note facility established with Obsidian Global GP, LLC

Neurizon Therapeutics Limited (ASX: NUZ) has secured adequate funding for its participation in the HEALEY ALS Platform Trial, an adaptive pivotal registration Phase 2/3 clinical trial for its lead asset, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The total funding package includes firm commitments from new and existing sophisticated and professional investors to raise ~$7.1 million through a placement, as well as a $20 million strategic funding facility from New York-based investment manager, Obsidian Global GP, LLC. Additionally, Neurizon will conduct a 2-for-5 pro rata non-renounceable entitlement offer to Eligible Shareholders to raise up to ~$17.1 million. This funding package, together with existing cash reserves and future AusIndustry R&D tax rebates, will fund the Company's participation in the HEALEY ALS Platform Trial. The HEALEY ALS Platform Trial is a multicentre, double-blind, placebo-controlled, adaptive Phase 2/3 trial for ALS created in partnership with the Network of Excellence for ALS (NEALS). The trial consists of 2 phases, a Randomised Clinical Trial (RCT) phase and an Active Treatment Extension (ATE) phase, both of 36 weeks in duration. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies, including Neurizon's lead asset, NUZ-001. Any additional capital raised through the Entitlement Offer will be used for working capital purposes, including ongoing pre-clinical initiatives associated with Neurizon's broader goal to leverage NUZ-001 as a platform molecule for innovation and treatment across a range of neurodegenerative diseases.

The funding package, which includes a placement, entitlement offer, and $20 million convertible note facility, will fund the company's participation in the HEALEY ALS Platform Trial over the next 2 years.

The new funding fundamentally transforms Neurizon's position and reflects the market's recognition of NUZ-001 as a Phase 3-ready asset of international significance. Participation in the HEALEY ALS Platform Trial places NUZ-001 at the centre of the most important and efficient clinical development framework for ALS treatment solutions globally, enabling Neurizon to further evaluate the promising safety and early efficacy signals observed to date in a larger clinical setting, while also advancing commercial, partnering and broader platform opportunities for NUZ-001 across multiple neurodegenerative diseases.